Literature DB >> 7865290

Serological responses to candidate AIDS vaccines.

B S Graham1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1994        PMID： 7865290

Source DB:  PubMed          Journal:  AIDS Res Hum Retroviruses        ISSN： 0889-2229            Impact factor:   2.205


× No keyword cloud information.
  7 in total

1.  A human immunodeficiency virus prime-boost immunization regimen in humans induces antibodies that show interclade cross-reactivity and neutralize several X4-, R5-, and dualtropic clade B and C primary isolates.

Authors:  F Verrier; S Burda; R Belshe; A M Duliege; J L Excler; M Klein; S Zolla-Pazner
Journal:  J Virol       Date:  2000-11       Impact factor: 5.103

2.  Induction of neutralizing antibodies and gag-specific cellular immune responses to an R5 primary isolate of human immunodeficiency virus type 1 in rhesus macaques.

Authors:  D C Montefiori; J T Safrit; S L Lydy; A P Barry; M Bilska; H T Vo; M Klein; J Tartaglia; H L Robinson; B Rovinski
Journal:  J Virol       Date:  2001-07       Impact factor: 5.103

3.  A molecularly cloned, pathogenic, neutralization-resistant simian immunodeficiency virus, SIVsmE543-3.

Authors:  V Hirsch; D Adger-Johnson; B Campbell; S Goldstein; C Brown; W R Elkins; D C Montefiori
Journal:  J Virol       Date:  1997-02       Impact factor: 5.103

4.  In vitro antigen challenge of human antibody libraries for vaccine evaluation: the human immunodeficiency virus type 1 envelope.

Authors:  P W Parren; P Fisicaro; A F Labrijn; J M Binley; W P Yang; H J Ditzel; C F Barbas; D R Burton
Journal:  J Virol       Date:  1996-12       Impact factor: 5.103

5.  Regional clustering of shared neutralization determinants on primary isolates of clade C human immunodeficiency virus type 1 from South Africa.

Authors:  Renata Bures; Lynn Morris; Carolyn Williamson; Gita Ramjee; Mark Deers; Susan A Fiscus; Salim Abdool-Karim; David C Montefiori
Journal:  J Virol       Date:  2002-03       Impact factor: 5.103

6.  Neutralizing antibodies in sera from macaques infected with chimeric simian-human immunodeficiency virus containing the envelope glycoproteins of either a laboratory-adapted variant or a primary isolate of human immunodeficiency virus type 1.

Authors:  D C Montefiori; K A Reimann; M S Wyand; K Manson; M G Lewis; R G Collman; J G Sodroski; D P Bolognesi; N L Letvin
Journal:  J Virol       Date:  1998-04       Impact factor: 5.103

Review 7.  HIV preventive vaccines. Progress to date.

Authors:  J Esparza; S Osmanov; W L Heyward
Journal:  Drugs       Date:  1995-11       Impact factor: 9.546
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.